Background: Metabolic syndrome (MS) is a combination of comorbidities that increase pro-inflammatory cytokines (PIC) production, with subsequent body composition (BC) abnormalities and high cardiovascular risk. Treatment with diet and exercise has been suggested as possible non-pharmacological adjuvant treatment. Objective: To determine changes in BC and PIC in patients with MS after a Mediterranean-type diet (MedDiet) and/or isokinetic exercise (IE). Methods: A controlled randomized clinical trial was conducted at a third-level hospital in Mexico City. Intervention groups: G1: MedDiet + IE; G2: IE; G3: MedDiet; G4: control. Anthropometry, BC, and PIC were collected from the baseline and at 12 weeks post-intervention. MedDiet was estimated from a 24-h recall record. IE consisted of a standard high-intensity anaerobic exercise program. Results: Forty-two patients with MS aged 18–65 years old were included. The most frequent comorbidities were obesity, insulin resistance, and dyslipidemia. After 6 months of intervention, a significant reduction of resistin was observed within the IE group and MedDiet + IE, whereas the former group also showed an increase in adiponectin. Interventions of MedDiet and MedDiet + IE showed a decrease in IL-10. Regarding BC, all groups increased the resistance values in relation to the baseline but were lower than the control group. Conclusions: The results suggest that MedDiet and IE have a selective impact on pro-inflammatory mediators, while the combination of MedDiet and IE may induce only minor changes in BC.
Background: Sarcopenia is a progressive muscle disorder associated with metabolic syndrome (MS), in which early impairments in muscle strength and quality precede muscle mass loss. Simple, non-invasive measures such as handgrip strength, estimated appendicular skeletal muscle mass (eASM), and phase angle (PA) may aid early detection, while adipokines link muscle dysfunction to metabolic regulation. Objective: In the present study, we aimed to evaluate the association between sarcopenia markers and PA in patients with MS. Methods: A cross-sectional study was conducted in patients with MS, at a third-level hospital in Mexico City. Sarcopenia was assessed by handgrip strength and eASM; body composition and PA were measured using bioelectrical impedance; and plasma adipokines were quantified by ELISA. Results: Seventy-four (mean age, 57.7 years; 75% female; BMI, 32.5 kg/m2) participants with MS were included. Handgrip strength correlated with eASM (r = 0.64; p < 0.01) and PA (rho = 0.43; p < 0.01), and eASM also correlated with PA (rho = 0.40; p < 0.01) and predicted higher PA values (OR = 2.74; p = 0.042). The sarcopenic subgroup had lower brachial circumference and plasma adiponectin. Conclusions: Sarcopenia is frequent in MS and associated with lower adiponectin, suggesting a vulnerable condition. Functional/structural markers of sarcopenia showed significant correlation with PA, whereas combined methods may enhance the early detection and management of muscle deterioration in metabolic disease.